Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2016

“The Report Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Global Markets Directs, Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Download Sample copy of this Report at



– The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)

– The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects

– The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Opioid-Induced Constipation (OIC) Overview 7

Therapeutics Development 8

Pipeline Products for Opioid-Induced Constipation (OIC) – Overview 8

Pipeline Products for Opioid-Induced Constipation (OIC) – Comparative Analysis 9

Opioid-Induced Constipation (OIC) – Therapeutics under Development by Companies 10

Opioid-Induced Constipation (OIC) – Therapeutics under Investigation by Universities/Institutes 11

Opioid-Induced Constipation (OIC) – Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Opioid-Induced Constipation (OIC) – Products under Development by Companies 15

Opioid-Induced Constipation (OIC) – Products under Investigation by Universities/Institutes 16

Opioid-Induced Constipation (OIC) – Companies Involved in Therapeutics Development 17

Develco Pharma Schweiz AG 17

Ironwood Pharmaceuticals, Inc. 18

Shionogi & Co., Ltd. 19

Sucampo Pharmaceuticals, Inc. 20

Synergy Pharmaceuticals, Inc. 21

Theravance Biopharma, Inc. 22

Valeant Pharmaceuticals International, Inc. 23

Opioid-Induced Constipation (OIC) – Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

(axelopran sulfate + oxycodone hydrochloride) – Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

axelopran sulfate – Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

dolcanatide – Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

linaclotide – Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

lubiprostone – Drug Profile 47

Product Description 47

Mechanism Of Action 47

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz